Inozyme Pharma Inc. (INZY): Price and Financial Metrics
INZY Price/Volume Stats
| Current price | $5.99 | 52-week high | $7.24 |
| Prev. close | $5.89 | 52-week low | $0.99 |
| Day low | $5.79 | Volume | 333,400 |
| Day high | $6.10 | Avg. volume | 1,202,379 |
| 50-day MA | $5.59 | Dividend yield | N/A |
| 200-day MA | $3.11 | Market Cap | 263.77M |
INZY Stock Price Chart Interactive Chart >
Inozyme Pharma Inc. (INZY) Company Bio
Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
Latest INZY News From Around the Web
Below are the latest news stories about INOZYME PHARMA INC that investors may wish to consider to help them evaluate INZY as an investment opportunity.
Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights- Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into the fourth quarter of 2024 - BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for t |
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment |
A number of insiders bought Inozyme Pharma, Inc. (NASDAQ:INZY) stock last year, which is great news for shareholdersIt is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... |
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company’s senior vice president and chief scientific officer, will present recently announced preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency in an oral presentati |
Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare ConferenceBOSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 from 9:30-10:10am ET. A live webc |
INZY Price Returns
| 1-mo | 3.10% |
| 3-mo | 109.44% |
| 6-mo | 324.82% |
| 1-year | 62.33% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 470.48% |
| 2022 | -84.60% |
| 2021 | -66.96% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...